April 23, 2010 – “So far, companies including Johnson & Johnson, Eli Lilly, Abbott, Amgen and Gilead have

April 22, 2010 – According to a new technical market research report, Biological Therapies for Cancer:

November 20 – KINAXO Biotechnologies GmbH announces the completion of a financing round, gaining two new investors in the company, Leifina and Conmit Invest. At the same time KINAXO reports that Jürgen Schumacher has been elected as a new member of the company’s advisory board.

Nov.3 – Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009.

August 10 – QIAGEN N.V. (Nasdaq: QGEN) today announced the results of operations for the second quarter and the six-month period ended June 30, 2009.

May 4 – QIAGEN N.V. (Nasdaq: QGEN) today announced the results of operations for its first quarter ended March 31, 2009.

February 9 – QIAGEN N.V. (Nasdaq: QGEN) today announced preliminary unaudited results of operations for the fourth quarter and the fiscal year ended December 31, 2008.

Sloning BioTechnology and Roger Kornberg’s group at Stanford University are working on a project to synthesize a gene mutant library where selected codons are introduced in a statistically expected and controlled ratio at preselected

Nabi Biopharmaceuticals reported today that total revenues for the full year ended December 31, 2005 were $108.1 million compared to $179.8 million in 2004. A decrease in revenues was expected and was primarily driven by the March 2005 expiration of a ten-year agreement to distribute WinRho SDF ([Rho(D) Immune Globulin (Human)] in the U.S. In [...]